Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Dec 8;15:899–912. doi: 10.2147/BCTT.S434973

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 Hu et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

HR-positive breast cancer xenograft models were treated with abemaciclib and TQB3616, and their respective anticancer effects in vivo were analyzed. Over 33 days, immunodeficient mice were administered PBS (vehicle), abemaciclib (50 mg/kg/day), or TQB3616 (50 mg/kg/day). (A) Photographs showing resected tumors. (B and C) Tumor growth curve and tumor weights. (D) A change in weight was observed in mice within three days of the first treatment. (E) The percentage of inhibited mRNA expression of 12 cell cycle-related or apoptosis-regulating genes in tumors collected from each treatment group and compared to that in the empty vector group. (F) Protein expression levels in xenograft tumors from each treatment group. **p<0.01, ***p<0.001, ****P<0.0001.